The aim of this study was to investigate the expression of receptor for advanced glycation end products (RaGe) on the surface of circulating endothelial cells (cecs) in patients with Kawasaki disease (KD).
K
awasaki disease (KD), an acute febrile disease that usually occurs in children under 5 y of age (1) , has become the primary cause of acquired heart disease in children (2, 3) . KD affects predominantly small-and medium-size arteries, particularly the coronary artery (4), with potential risks for coronary stenosis and thrombosis caused by coronary artery lesions (CALs), and even death caused by myocardial infarction (5, 6) . CALs can be found in about 10-15% of children with KD (7) . Although the treatment with intravenous immunoglobulin (IVIG) for patients with KD in the acute stage (A-KD) can reduce the duration of fever and the incidence of CALs, ~10% of children with KD do not respond to IVIG treatment and therefore have higher risk for CALs (8, 9) . Both the etiology and pathogenesis of KD remain unclear (10) .
Endothelial damage is the basic pathologic process in the development of many diseases. Circulating endothelial cells (CECs) represent a new sensitive indicator for studying vascular endothelial function in vivo (11) . CALs caused by KD are closely related to the function of coronary artery endothelial cells, and the CEC levels increase significantly in the blood of patients with A-KD (12) . S100A12 is mostly expressed in human granulocytes. S100A12 exerts proinflammatory effects by eliciting a transient infiltration of neutrophils and more delayed recruitment of monocytes at inflammatory sites, activating endothelial cells and leukocytes, and potently chemoattracting monocytes, which is a key process, especially in vasculitis (13) (14) (15) (16) (17) (18) (19) . S100A12 is the first member of the S100 protein family shown to engage the multiligand receptor for advanced glycation end products (RAGE) and to exert its regulatory effects on target cells via RAGE binding. RAGE engagement by S100A12 in leukocytes and endothelial cells results in activation of nuclear factor-κB with resulting activation of proinflammatory genes. S100A12/RAGE interactions appear to be functionally important in human pathologies (20) (21) (22) . Many studies showed that S100A12 has a close relation with KD (23) (24) (25) (26) . Our studies found that CECs increased significantly in KD patients; the S100A12 expression on the surface of CECs increased significantly in KD patients and persisted for a longer time in patients with CALs (27) , raising the possibility that S100A12 might have a role in the pathophysiology of KD via RAGE engagement.
There has been no report on the expression of RAGE on the surface of CECs in patients with KD. To determine whether there is relationship between KD and RAGE on the surface of CECs, we investigated the positive rate of RAGE on the surface of CECs (CECs-RAGE/CECs), and the fluorescence intensity (FI) of RAGE on the surface of CECs (FI-RAGE-CECs) by monoclonal antibody combined with flow cytometry in KD patients with or without CALs, and in IVIG-respondent or IVIG-resistant KD patients in acute (A-KD), subacute (SA-KD), and convalescent (C-KD) stages.
The CECs-RAGE/CECs and FI-RAGE-CECs levels were significantly (P < 0.05) higher in KD patients with CALs than in the controls. The FI-RAGE-CECs levels were significantly (P < 0.05) higher in SA-KD and C-KD patients than in A-KD patients ( Table 2) .
CECs-RAGE/CECs and FI-RAGE-CECs Levels in IVIG-Resistant KD
The CECs-RAGE/CECs and FI-RAGE-CECs levels were significantly (P < 0.05) higher in IVIG-resistant KD patients than in the controls. The CECs-RAGE/CECs were significantly (P < 0.05) higher in C-KD patients than in A-KD and SA-KD patients (P < 0.05). The FI-RAGE-CECs levels increased progressively in SA-KD and C-KD patients ( Table 3) .
Comparison of CECs-RAGE/CECs and FI-RAGE-CECs Levels in KD With and Without CALs
The CECs-RAGE/CECs rate was significantly (P < 0.05) higher in C-KD patients with CALs than in those without CALs. The FI-RAGE-CECs levels were significantly (P < 0.05) lower in A-KD patients with CALs than in those without CALs and decreased progressively in SA-KD and C-KD patients without CALs (Figure 1) .
Comparison of CECs-RAGE/CECs and FI-RAGE-CECs Levels in IVIG-Respondent and IVIG-Resistant KD Patients
In SA-KD and C-KD, the CECs-RAGE/CECs and FI-RAGECECs levels were significantly (P < 0.05) higher in IVIGresistant patients than in IVIG-respondent patients. But the FI-RAGE-CECs level was significantly (P < 0.05) lower in IVIG-resistant A-KD patients than in IVIG-respondent A-KD patients. The CECs-RAGE/CECs and FI-RAGE-CECs levels decreased in IVIG-respondent SA-KD and C-KD patients but increased progressively in IVIG-resistant SA-KD and C-KD patients (Figure 2 ).
DiSCUSSiOn
In this study, we found that the expression levels of RAGE on the surface of CECs in patients with KD were upregulated and did not decrease significantly in SA-KD or C-KD; the expression levels of RAGE were similar to the expression levels of S100A12 found on the surface of CECs in patients with KD (27) . This suggests that the high levels of S100A12 on the surface of CECs may stimulate the expression of RAGE on the surface of CECs in patients with KD. This study corroborates the concept that the expression of RAGE is upregulated in presence of its own ligand by a positive feedback loop mechanism, that RAGE participates in the pathophysiology of KD, and that the S100A12-RAGE pathway may be crucial in the pathogenesis of KD.
Several studies (14) demonstrate that the activation of RAGE by S100A12 results in upregulated expression of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1β, by other phagocytes. Released tumor necrosis factor may stimulate granulocytes to secrete S100A12, thereby establishing a self-amplifying positive feedback loop. S100A12-activated peripheral blood mononuclear cells release interleukin-2 and show enhanced expression of cytokines (14) . RAGE expression increases whenever its ligands accumulate (20) , and RAGE-ligand interaction leads to physiological and pathological processes, including diabetic complications, neurodegenerative disorders, atherosclerosis, and inflammation (21, 28) . However, the full extent of RAGE expression and the molecular Articles Gong et al.
mechanisms that control it have not been evaluated adequately. Understanding the role of RAGE in development could provide insights to pursue the reduction of RAGE-mediated CALs in KD.
Mahajan et al. reported that C-reactive protein upregulated the expression of RAGE in a dose-and time-dependent manner in the THP-1 monocytic cell line (29) . Zhong et al. reported that the expression of RAGE in human endothelial cells was found to be increased in the presence of C-reactive protein and suggested that C-reactive protein enhances the ability of RAGE to bind to its ligands (30) . The clinical characteristics of this group of KD patients showed that C-reactive protein increased significantly in A-KD and decreased significantly in SA-KD. We did not find the correlation between C-reactive protein levels and the expression levels of RAGE on the surface of CECs in patients with KD. However, it is possible that C-reactive protein can stimulate the expression of RAGE on the surface of CECs in A-KD patients. Although C-reactive protein levels decrease quickly in SA-KD patients, the elevated expression levels of RAGE on the surface of CECs in patients with KD can persist for a longer time.
The study found that the FI-RAGE-CECs levels were higher in SA-KD and C-KD patients than in A-KD patients with CALs, but decreased progressively in SA-KD and C-KD patients without CALs; the CECs-RAGE/CECs rate was higher in C-KD patients with CALs than in those without CALs. This suggests that the endothelial cell lesions can be alleviated in SA-KD and C-KD patients without CALs and can be aggravated in SA-KD and C-KD patients with CALs. It is possible that the persistence of inflammation is longer in KD patients with CALs than in those without CALs. The FI-RAGE-CECs levels were significantly lower in IVIG-resistant A-KD patients than in IVIG-respondent A-KD patients. In IVIG-resistant SA-KD and C-KD patients, the CECs-RAGE/CECs and FI-RAGE-CECs levels increased progressively and were higher than in IVIG-respondent SA-KD and C-KD patients. This illustrates that the expression levels of RAGE on the surface of CECs in patients with KD is correlated with IVIG-resistant or IVIG-respondent patients, and 
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the effect by which IVIG reduces the pathological changes of endothelial cells is weaker in IVIG-resistant patients than in IVIG-respondent patients. This suggests that the inflammation is more severe in KD patients with CALs and IVIG-resistant KD patients than in KD patients without CALs or IVIG-respondent KD patients. It demonstrates further that the S100A12-RAGE pathway participates in the pathogenesis of KD. In summary, the expression levels of RAGE on the surface of CECs are upregulated in KD patients. The upregulated expression levels of RAGE on the surface of CECs can be alleviated in SA-KD and C-KD patients without CALs and can be aggravated in SA-KD and C-KD patients with CALs. In IVIGresistant SA-KD and C-KD patients, the expression levels of RAGE on the surface of CECs increase progressively and are higher than in IVIG-respondent SA-KD and C-KD patients. This suggests that RAGE expression on CECs is involved in the pathophysiology of KD.
MetHODS
The study was approved by the ethical committee of the Children's Hospital, Zhejiang University School of Medicine, and based on the institution's guidelines for human studies. The investigation conformed to the principles outlined in the Declaration of Helsinki. Informed consent was obtained from all the subjects.
Subjects
Eighty-nine KD patients (52 males and 37 females), aged 3-152 mo (28.2 ± 24.6 mo) were enrolled. The duration of fever was 4-10 d (5.6 ± 3.4 d). The erythrocyte sedimentation rate and C-reactive protein were 78 ± 33 mm/h and 92 ± 55 mg/l, respectively, in acute-stage KD patients, and 87 ± 34 mm/h and 13 ± 25 mg/l, respectively, in subacutestage KD patients. All the patients were treated with IVIG at 1 g/kg/d for 2 d and oral aspirin at 30-50 mg/kg/d. After 3-5 d of treatment, when the patient's temperature returned to normal, the dose of aspirin was reduced to 3-5 mg/kg/d for 12 wk. There were seven IVIGresistant KD patients (5 males and 2 females), aged 6-122 mo (24.8 ± 25.4 mo), whose temperature was still higher than 38 °C after 48 h of standard treatment; these were continued with IVIG at 1 g/kg/d for another 2 d. All the KD patients fulfilled the diagnostic criteria established by the Kawasaki Disease Research Committee (31) . Fifteen patients (9 males and 6 females), aged 6-97 mo (23.8 ± 21.2 mo), were found with CALs (defined as coronary artery z-score >5 (32)) by echocardiography during the disease process; four of the patients with CALs had IVIG-resistant KD. Dipyridamole and warfarin were added in patients with CALs depending on the severity of CALs.
The disease process durations between 4 and 10 d, 11 and 21 d, and 22 and 60 d were defined as A-KD, SA-KD, and C-KD, respectively. Thirty-eight healthy children (21 males and 17 females), aged 5-144 mo (27.6 ± 26.2 mo), were enrolled in the control group.
Blood Samples
Two milliliters of venous blood samples were collected in 89 KD patients (three times for each patient), including acute stage before IVIG treatment, subacute stage (mean (range): 15 (13-18) d), and convalescent stage (30 (28-34) d), and in 38 healthy children, and anticoagulated with 1:10 heparin. Anticoagulated blood samples were kept at 4 °C and analyzed by flow cytometry within 2 h of venesection. The samples were divided into two tubes (each with 100 µl): one tube was used for testing by adding 10 µl monoclonal goat antihuman RAGE antibody (R&D systems), and the other was used as control by adding goat IgG1. After 30 min, both tubes were washed once using PBS, then incubated with fluorescein isothiocyanate-labeled rabbit anti-goat IgG (Southern Biotech) for 30 min. After washing twice with PBS and removing the supernatant, the control tube was stained with 5 µl CD45-PerCP mAb (CD45 monoclonal antibody was conjugated with peridinin-chlorophyll-α-protein, USA Becton Dickinson) and mouse IgG1-Phycoerythrin (PE), while the testing tube was stained with 5 µl CD45-PerCP mAb and 5 µl CD146-PE mAb (CD146 monoclonal antibody was conjugated with R-phycoerythrin, USA Becton Dickinson). After incubation at 4 °C for 20 min, 400 µl hemolytic agent (FACSTM, USA Becton Dickinson) was added to each of the two tubes; after 10 min the tubes were centrifuged at 1,000 rpm for 10 min. Finally, 500 µl PBS was added to each of the two tubes and mixed well to be detected after removal of the supernatant.
Flow Cytometry
The samples in both tubes were evaluated by flow cytometry (FACS Calibur, USA Becton Dickinson). Flow cytometry data were analyzed with CellQuest software. A multistep manual technique was used to detect and quantify the CECs and RAGE on surface of the CECs; 100,000 cells were detected including mononuclear cells (lymphocytes, monocytes, and CECs) and polymorphonuclear leukocytes, and data were kept in the computer. Excitation light sources were 488 nm for fluorescein isothiocyanate, PE, and PerCP. 
